Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vigil Neuroscience, Inc. (VIGL)

10.94   0.29 (2.72%) 02-02 15:21
Open: 10.7 Pre. Close: 10.65
High: 11.0209 Low: 10.55
Volume: 4,659 Market Cap: 389(M)

Technical analysis

as of: 2023-02-02 3:15:51 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 13.92     One year: 15.13
Support: Support1: 10.23    Support2: 8.51
Resistance: Resistance1: 11.92    Resistance2: 12.96
Pivot: 11.31
Moving Average: MA(5): 10.82     MA(20): 11.49
MA(100): 11.59     MA(250): 8.86
MACD: MACD(12,26): -0.4     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 12.8     %D(3): 15.5
RSI: RSI(14): 42.3
52-week: High: 18.27  Low: 2.18
Average Vol(K): 3-Month: 36 (K)  10-Days: 13 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ VIGL ] has closed above bottom band by 27.6%. Bollinger Bands are 34.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.72 - 10.78 10.78 - 10.82
Low: 10.5 - 10.57 10.57 - 10.63
Close: 10.55 - 10.66 10.66 - 10.75

Company Description

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 01 Feb 2023
Northpond Ventures, LLC's Top - GuruFocus.com

Wed, 25 Jan 2023
Is Vigil Neuroscience Inc (VIGL) a Bad Choice in Biotechnology Wednesday? - InvestorsObserver

Mon, 23 Jan 2023
Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving ... - Investing.com UK

Wed, 18 Jan 2023
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Average Rating ... - MarketBeat

Tue, 29 Nov 2022
Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation - Simply Wall St

Mon, 28 Nov 2022
Watch This Alpinist Seek the Threshold of Commitment - GearJunkie

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 5 (M)
% Held by Insiders 12.8 (%)
% Held by Institutions 114.3 (%)
Shares Short 293 (K)
Shares Short P.Month 298 (K)

Stock Financials

EPS 0
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) 0
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.77
Qtrly Earnings Growth 0
Operating Cash Flow -61 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.